Brief: Everest Medicines Says Center For Drug Evaluation Of NMPA Recommended Breakthrough Therapy Designation For Nefecon
02/12/2020 01:03
Dec 2 (Reuters) - Everest Medicines Ltd 1952.HK :
* CHINA CENTER FOR DRUG EVALUATION OF NMPA RECOMMENDED
BREAKTHROUGH THERAPY DESIGNATION FOR NEFECON FOR TREATMENT OF
IGA NEPHROPATHY
Source text for Eikon: ID:nHKSbFHysV
Further company coverage: 1952.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region